BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ConSynance Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ConSynance Therapeutics's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07348601-221@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:CSTI-500: Phase 2 readout est. (NCT07348601)
DESCRIPTION:CSTI-500\, phase 2\, Prader-Willi Syndrome.\nStudy: A Study of 
 CSTI-500 in Patients With Prader-Willi Syndrome\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/csti-
 500#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07348601
URL:https://assetmemo.bio/drug/csti-500#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
